These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2572264)

  • 1. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function.
    Rousseau MF; Pouleur H; Debaisieux JC; Van Eyll C; Charlier AA
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):84S-85S. PubMed ID: 2572264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
    Tomlinson B; Cruickshank JM; Hayes Y; Renondin JC; Lui JB; Graham BR; Jones A; Lewis AD; Prichard BN
    Br J Clin Pharmacol; 1990 Nov; 30(5):665-72. PubMed ID: 1980200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamics in postural hypotension--effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol.
    Mehlsen J; Trap-Jensen J
    Eur Heart J; 1990 Apr; 11 Suppl A():56-8. PubMed ID: 1971593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute haemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol at rest and during supine exercise in patients with left ventricular dysfunction due to ischaemic heart disease: a double-blind randomized trial.
    de Feyter PJ; Serruys PW
    Eur Heart J; 1990 Apr; 11 Suppl A():48-9. PubMed ID: 1971590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease.
    Pouleur H; van Eyll C; Etienne J; van Mechelen H; Vuylsteke A; Rousseau MF
    Basic Res Cardiol; 1989; 84 Suppl 1():157-62. PubMed ID: 2573338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity.
    Böhm M; Mittmann C; Schwinger RH; Erdmann E
    Am Heart J; 1990 Dec; 120(6 Pt 1):1381-92. PubMed ID: 1978979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.
    Pouleur H; van Eyll C; Hanet C; Cheron P; Charlier AA; Rousseau MF
    Circulation; 1988 May; 77(5):1081-9. PubMed ID: 2896076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The electrophysiological effects of intravenous xamoterol in man.
    Bowes RJ; Gautam PC; Graham DR; Harley A
    Eur J Clin Pharmacol; 1986; 29(6):731-4. PubMed ID: 2872057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
    Hattori Y; Sakuma I; Nakao Y; Kanno M
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Illustration of the effects of long-term xamoterol therapy on the time course of left ventricular pressure.
    van Mechelen H; Ries A; Pouleur H; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():67-9. PubMed ID: 1971598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog.
    Hadfield SE; Slee SJ; Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):78S-81S. PubMed ID: 2572262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro pharmacology of xamoterol (ICI 118,587).
    Malta E; Mian MA; Raper C
    Br J Pharmacol; 1985 May; 85(1):179-87. PubMed ID: 2862938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of beta-adrenoceptor partial agonists in patients with postural hypotension.
    Mehlsen J; Stadeager C; Trap-Jensen J
    Eur J Clin Pharmacol; 1993; 44(1):7-11. PubMed ID: 8436159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate central and regional haemodynamic effects of a new beta 1-adrenergic stimulating drug, xamoterol (Corwin) in healthy volunteers.
    Tangø M; Carlsen JE; Trap-Jensen J
    Eur J Clin Pharmacol; 1985; 29(2):155-8. PubMed ID: 2866963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.
    Lammers JW; Müller ME; Folgering HT; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated?
    Jakubetz J; Schmuck S; Poller U; Fuchs B; Gorf A; Radke J; Pönicke K; Brodde OE
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):461-72. PubMed ID: 10069683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.